Figure 2.
Figure 2. Baseline vs end-of-infusion p65-phospho NF-κB iNKT cell activation. Points below the black line represent patients who achieved the primary outcome measure of a p65-phospho-NF-κB iNKT cell activation at 48 hours that was a >30% reduction from baseline. Subjects in the regadenoson and placebo arms are represented by red and white circles, respectively.

Baseline vs end-of-infusion p65-phospho NF-κB iNKT cell activation. Points below the black line represent patients who achieved the primary outcome measure of a p65-phospho-NF-κB iNKT cell activation at 48 hours that was a >30% reduction from baseline. Subjects in the regadenoson and placebo arms are represented by red and white circles, respectively.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal